Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CVAC
CureVac N.V.
Ordinary Shares
9.84
-0.40
-3.90%
Delayed (15 Min) Trade Data: 04:00pm 08/31/2022
Overview
Quote
Company Profile
Security Details
News
Financials
Disclosure
Research
we don't show quote ?????
we don't show quote ?????
CureVac (CVAC) Receives a Buy from Berenberg Bank
August 23 2022 - 09:55PM
TipRanks
Alert
Print
Share On Facebook
In a report released yesterday, Zhiqiang Shu from Berenberg Bank maintained a Buy rating on CureVac (CVAC - Research Report), with a price target of $45.00. The company's shares closed yesterday at $11.32.Shu covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Arcus Biosciences, and Sutro Biopharma. According to TipRanks, Shu has an average return of -21.0% and a 23.78% success rate on recommended stocks. Currently, the analyst consensus on CureVac is a Moderate Buy with an average price target of $28.50, implying a 151.77% upside from current levels.
https://www.tipranks.com/news/blurbs/curevac-cvac-receives-a-buy-from-berenberg-bank?utm_source=advfn.com&utm_medium=referral
CVAC
CureVac NV
12.62
-0.03 (-0.24%)
Volume: 276,718
Day Range: 12.39 - 12.79
Bid: 12.60
Ask: 13.18
Last Trade Time: 4:57:18 PM EDT
Total Trades: 3,775
CVAC Detailed Quote
Interesting new Beneficial Owners recently. Taken an entry position today.
Looks like Covid-19 vaccines still hold prominent place in biotech research: "CureVac and GSK's second-generation vaccine candidate targeting two recent COVID-19 variants has been shown to be highly effective in preclinical studies on mice, CureVac said, as it seeks to catch up with rivals' development work." https://finance.yahoo.com/news/1-curevac-gsks-experimental-covid-124419805.html
CureVac NV (CVAC)
18.18 ? -0.65 (-3.45%)
Volume: 402,327 @06/03/22 6:58:05 PM EDT
Bid Ask Day's Range
17.61 20.1 17.56 - 18.58
CVAC Detailed Quote
CureVac NV (CVAC)
18.18 ? -0.65 (-3.45%)
Volume: 402,327 @06/03/22 6:58:05 PM EDT
Bid Ask Day's Range
17.61 20.1 17.56 - 18.58
CVAC Detailed Quote
CureVac NV (CVAC)
17.205 ? 0.625 (3.77%)
Volume: 164,845 @04/29/22 1:27:43 PM EDT
Bid Ask Day's Range
17.2 17.25 16.47 - 17.44
CVAC Detailed Quote
CureVac NV (CVAC)
15.69 ? -1.08 (-6.44%)
Volume: 305,719 @03/11/22 5:11:50 PM EST
Bid Ask Day's Range
15.7 16.66 15.68 - 17.225
CVAC Detailed Quote
CureVac NV (CVAC)
18.19 ? 0.05 (0.28%)
Volume: 587,579 @02/04/22 5:09:58 PM EST
Bid Ask Day's Range
17.05 19.74 17.7685 - 18.61
CVAC Detailed Quote
CureVac Says Preclinical Trial Shows Antibody Levels of COVID-19 Vaccine Candidate CV2CoV 'Highly Comparable' With Pfizer's mRNA Vaccine
MT NEWSWIRES 3:11 PM ET 11/18/2021
03:11 PM EST, 11/18/2021 (MT Newswires) -- CureVac(CVAC) said Thursday the extended preclinical study of the second-generation vaccine candidate, CV2CoV, showed that neutralizing antibody levels after full vaccination of animals were "highly comparable" with Pfizer (PFE) and BioNTech's (BNTX) licensed mRNA vaccine, Comirnaty.
CureVac (CVAC) is developing CV2CoV in partnership with GlaxoSmithKline (GSK). Animals were vaccinated with either 12 micrograms of CV2CoV or a 30 microgram standard dose of Comirnaty.
Data showed that targeted optimizations of a non-chemically modified mRNA can significantly improve immune responses in a preclinical model.
CureVac NV (CVAC)
38.0 ? -3.47 (-8.37%)
Volume: 1,621,942 @11/05/21 7:55:54 PM EDT
Bid Ask Day's Range
38.02 38.19 36.32 - 39.33
CVAC Detailed Quote
CureVac NV (CVAC)
38.64 ? -2.83 (-6.82%)
Volume: 1,620,537 @11/05/21 4:05:48 PM EDT
Bid Ask Day's Range
38.0 38.2 36.32 - 39.33
CVAC Detailed Quote
GOOD PHARMA STUFF $CVAC
took a starter today...have a great weekend
CureVac NV (CVAC)
43.77 ? -0.33 (-0.75%)
Volume: 250,572 @10/08/21 6:03:51 PM EDT
Bid Ask Day's Range
42.5 43.89 43.1 - 44.68
CVAC Detailed Quote
Historic short interest:
You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest
Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch
Settlement Date Short Interest Percent Change
Average Daily Share Volume Days to Cover
09/15/2021 4,542,534 (2.16) 456,619 9.95
08/31/2021 4,642,803 2.07 773,263 6.00
08/13/2021 4,548,677 12.42 801,889 5.67
07/30/2021 4,046,124 11.49 512,482 7.90
07/15/2021 3,629,162 (12.86) 1,078,867 3.36
06/30/2021 4,164,654 41.83 3,559,106 1.17
06/15/2021 2,936,456 (0.57) 910,303 3.23
05/28/2021 2,953,400 (7.46) 578,186 5.11
05/14/2021 3,191,412 64.16 1,427,744 2.24
04/30/2021 1,944,116 17.05 1,256,431 1.55
04/15/2021 1,660,871 20.49 676,177 2.46
03/31/2021 1,378,464 2.92 808,797 1.70
03/15/2021 1,339,328 30.98 853,277 1.57
02/26/2021 1,022,578 52.16 798,158 1.28
02/12/2021 672,026 (46.44) 1,037,097 1.00
01/29/2021 1,254,801 10.19 627,726 2.00
01/15/2021 1,138,723 45.52 424,328 2.68
12/31/2020 782,533 (9.30) 506,131 1.55
12/15/2020 862,726 (20.29) 909,921 1.00
11/30/2020 1,082,373 (17.16) 560,942 1.93
11/13/2020 1,306,648 18.03 522,433 2.50
10/30/2020 1,107,080 11.54 324,945 3.41
10/15/2020 992,529 (11.81) 405,468 2.45
09/30/2020 1,125,437 (14.60) 367,068 3.07
This is not a COVID stock - applications for mRNA are much bigger than COVID.
The difference is in the MOA of the mRNA which is not disclosed.
mRNA tech is valid - It seems that the inadequately tested Pfizer vax is dangerous.
Calling something "mRNA" proves nothing. You have to identify the MOA of the mRNA.
Telomeres and cancer: https://www.nature.com/articles/nrm.2016.171
Overview of Telomeres: https://pubs.acs.org/doi/10.1021/acschembio.9b00945
Synthetic mRNA could re-engineer telomeres, but it could also destroy them:
https://www.theatlantic.com/ideas/archive/2021/03/how-mrna-technology-could-change-world/618431/
CureVac NV (CVAC)
55.3 ? 1.71 (3.19%)
Volume: 358,638 @09/22/21 5:14:00 PM EDT
Bid Ask Day's Range
54.53 56.0 52.83 - 55.67
CVAC Detailed Quote
CureVac NV (CVAC)
58.8 ? -0.78 (-1.31%)
Volume: 615,968 @08/13/21 7:25:07 PM EDT
Bid Ask Day's Range
56.28 59.4 58.16 - 60.75
CVAC Detailed Quote
CureVac NV (CVAC)
58.8 ? 0.07 (0.12%)
Volume: 463,829 @07/09/21 7:49:02 PM EDT
Bid Ask Day's Range
55.08 63.95 58.0 - 59.29
CVAC Detailed Quote
i got some @ $43 'CureVac B.V. (CVAC)'
CVAC-this was a good falling knife trade ;)
great thank you for sharing i did more in ibox just now. 'CureVac B.V. (CVAC)'
i think big time rally coming soon. too many hands in dis to go lower.
I'm lucky I got in early in October of 2020 at it's low of $43 so I am actually still in the positive.
$CVAC [-chart]www.curevac.com/wp-content/uploads/2020/06/curevac-logo-claim-gray-fin.svg[/chart]
https://www.curevac.com/en/about-us/
https://www.curevac.com/en/about-us/partnerships/
https://www.curevac.com/en/technology/
https://www.curevac.com/en/technology/production/
https://www.curevac.com/en/technology/publications/
https://www.curevac.com/en/pipeline/
https://www.curevac.com/en/newsroom/news/
https://www.curevac.com/en/investor-relations/overview/
https://www.curevac.com/en/investor-relations/financial-reports/
$CVAC also has big , huge pipeline too.
i decided to also. i bought near closing $52 i did not know shares are absolutely thin. $11 for trading.
I was working and didn't even see the drop or the news but just bought at $50.
About 11 mil. left for trading 3-1/2 % are shorted What Type Of Shareholders Own The Most Number of CureVac N.V. (NASDAQ:CVAC) Shares?
Simply Wall St
Wed, June 9, 2021, 11:47 PM·4 min read
https://finviz.com/quote.ashx?t=cvac&ty=c&ta=1&p=d
Insider Own 55.92%
Inst Own 23.40%
Shs Outstand 177.97M
Shs Float 82.25M
Short Float 3.59%
CVAC
-3.47%
The big shareholder groups in CureVac N.V. (NASDAQ:CVAC) have power over the company. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Warren Buffett said that he likes "a business with enduring competitive advantages that is run by able and owner-oriented people." So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.
With a market capitalization of US$21b, CureVac is rather large. We'd expect to see institutional investors on the register. Companies of this size are usually well known to retail investors, too. Taking a look at our data on the ownership groups (below), it seems that institutions are noticeable on the share registry. Let's delve deeper into each type of owner, to discover more about CureVac.
View our latest analysis for CureVac
ownership-breakdown
ownership-breakdown
What Does The Institutional Ownership Tell Us About CureVac?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
As you can see, institutional investors have a fair amount of stake in CureVac. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see CureVac's historic earnings and revenue below, but keep in mind there's always more to the story.
earnings-and-revenue-growth
earnings-and-revenue-growth
CureVac is not owned by hedge funds. Looking at our data, we can see that the largest shareholder is dievini Hopp BioTech holding GmbH & Co. KG with 42% of shares outstanding. KfW, Asset Management Arm is the second largest shareholder owning 16% of common stock, and GlaxoSmithKline plc holds about 8.0% of the company stock.
Story continues
Bad Efficacy news hit for their MRNA Covid Vaccine.
only 2.66 mil traded & dumped to under $40 a.h. CVAC
Bid: 50.25 Ask: 50.49 Last: 50.25 Chg ($): -47.95 Vol:
i bought da dipper $44 CureVac NV (CVAC)
CureVac NV (CVAC)
49.5 ? -48.7 (-49.59%)
Volume: 2,688,621 @06/16/21 7:18:16 PM EDT
Bid Ask Day's Range
49.5 49.65 93.92 - 101.0
CVAC Detailed Quote
$CVAC interesting day, closed @ 90 plus but right after a.h. boom da hatch man
Well that didn't go well. I should have sold @150. More disapointment but I own FCEL and PLUG so what's new.
Covid MRNA Falls short in trials. CVAC. Would be interesting to see the difference between theirs Moderna and Pfizer
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
177
|
Created
|
08/14/20
|
Type
|
Free
|
Moderators |
PARTNER
PARTNER
PARTNER
Respirational syncytial virus
PARTNER
DETAILS ON OTHER INFECTIOUS DISEASES
Rota, malaria, universal influenza
PARTNER
DETAILS ON VARIOUS PROJECTS
always like to check for a history of revenue growth. You can too, by accessing this free chart of historic revenue and earnings in this detailed graph.
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
https://finviz.com/quote.ashx?t=cvac&ty=c&ta=1&p=d
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments.
There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least.
Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Insider ownership is positive when it signals leadership are thinking like the true owners of the company.
However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
We can see that insiders own shares in CureVac N.V.. It is a very large company, and board members collectively own US$1.1b worth of shares (at current prices).
It is good to see this level of investment. You can check here to see if those insiders have been buying recently.
With a 21% ownership, the general public have some degree of sway over CureVac. While this group can't necessarily call the shots,
it can certainly have a real influence on how the company is run.
CureVac has entered into a collaboration with Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company,
to access the full suite of Arcturus’ lipid-mediated delivery intellectual property to enable the development of mRNA product candidates.
TÜBINGEN, Germany/ BOSTON, USA – August 14, 2020 – CureVac B.V. (“CureVac” or the “Company”), a clinical-stage biopharmaceutical company
developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the pricing of its
initial public offering of 13,333,333 common shares at an initial public offering price of $16.00 per common share, for total gross proceeds of approximately $213.3 million.
In addition, the Company has granted the underwriters a 30-day option to purchase up to an
additional 1,999,999 common shares at the public offering price, less underwriting discounts and commissions. All of the common shares are being offered by CureVac.
The shares are scheduled to begin trading on the Nasdaq Global Market today, August 14, 2020, under the ticker symbol “CVAC.”
The offering is expected to close on August 18, 2020, subject to customary closing conditions.
BofA Securities, Jefferies and Credit Suisse are acting as joint book-running managers for the proposed offering, with Berenberg and Kempen & Co acting as passive book-running managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (“SEC”) on August 13, 2020.
The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available,
for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the final prospectus, when available, may be obtained from
BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001,
by telephone at (800) 299-1322 or by email at dg.prospectus_requests@bofa.com; Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com;
and Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, North Carolina 27560, by telephone at (800) 221-1037 or by email at usa.prospectus@credit-suisse.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About CureVac
CureVac is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology with expertise in developing
and optimizing this versatile molecule for medical purposes.
The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.
The company applies its technologies for the development of prophylactic vaccines, cancer therapies,
antibody therapies and the treatment of protein therapies. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.
CureVac Investor Relation Contact
Dr. Sarah Fakih, Vice President Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com
CureVac Media Contact
Thorsten Schüller, Director Corporate Communications
CureVac, Tübingen, Germany
T: +49 7071 9883-1577
thorsten.schueller@curevac.com
sarah.fakih@curevac.com
*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |